IN8bio (NASDAQ: INAB)/b) announced publication of a review in titled “Harnessing γδ T cells through engineering and combination therapies.” The article, co-authored by CSO Lawrence Lamb, PhD, reviews γδ T cell engineering, T cell engagers, CAR-γδ T cells and cytokine-armored cells.
It discusses combination strategies with checkpoint inhibitors, chemotherapy, cytokines and bispecific antibodies, the potential for allogeneic “off-the-shelf” γδ T therapies with limited GvHD risk, and growing clinical evidence in solid tumors and hematologic cancers.
Loading...
Loading translation...
Positive
None.
Negative
None.
News Market Reaction – INAB
-1.28%
-1.28%News Effect
On the day this news was published, INAB declined 1.28%, reflecting a mild negative market reaction.
This announcement underscores IN8bio’s scientific leadership in γδ T cell engineering, with a Nature...
Analysis
This announcement underscores IN8bio’s scientific leadership in γδ T cell engineering, with a Nature Communications review detailing CAR-γδ T cells, cytokine-armored cells, and combination strategies. Recent history shows GBM data with mPFS of 13.0 months and mOS exceeding 19.5 months versus standard of care, alongside an effective $200,000,000 shelf and a $2,800,000 ATM program. Investors may watch upcoming clinical readouts, financing activity, and additional publications to gauge how this platform progresses from scientific promise toward late-stage development.
Key Figures
ATM size:$2,800,000ATM commission:3.0%Shelf capacity:$200,000,000+5 more
8 metrics
ATM size$2,800,000At-the-market common stock offering via JonesTrading (424B5, June 1, 2026)
ATM commission3.0%Sales agent fee on gross proceeds under ATM program
Shelf capacity$200,000,000Form S-3/A shelf registration filed May 18, 2026
Shares outstanding9,847,089 sharesCommon shares outstanding as of March 31, 2026 (424B5)
Non-affiliate value$17,932,668Aggregate market value of non-affiliate common stock as of June 1, 2026
mPFS13.0 monthsRepeat-dose DeltEx DRI GBM patients vs 6.6 months standard-of-care
mOS>19.5 monthsOverall survival for DeltEx DRI GBM patients vs 13.2 months standard-of-care
Gifted shares724,637 sharesCharitable transfer reported in Schedule 13D/A and Form 4 on May 27, 2026
Q4/FY 2025 results, GBM durability data, and private placement extending runway into H1 2027.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Recent INAB news — including positive clinical data, earnings updates, and corporate actions — has repeatedly been followed by negative 24-hour price reactions.
Recent Company History
Over the last six months, IN8bio has repeatedly highlighted progress in its γδ T cell programs and finances. Clinical updates in glioblastoma showed improved median progression-free survival of 13.0 months and overall survival exceeding 19.5 months versus standard of care. Earnings releases emphasized advancing IND-enabling work and a strengthened balance sheet, while other news covered conference presentations and employee equity grants. Despite this, each of these announcements saw negative next-day price moves, and today’s Nature Communications publication continues a pattern of the stock trading lower around seemingly constructive updates.
Key Terms
gamma-delta t cell, t cell engagers, car-gamma-delta t cells, checkpoint inhibitors, +4 more
8 terms
gamma-delta t cellmedical
"IN8bio, Inc. ... developing innovative gamma-delta (γδ) T cell therapies and T cell engagers"
A gamma-delta T cell is a specialized type of white blood cell that helps detect and respond to infected, damaged, or cancerous cells by recognizing common stress signals rather than individual molecular ID tags. Investors care because these cells are being explored as the basis for new immunotherapies, cell-based medicines and diagnostics—think of them like border guards that spot suspicious behavior instead of checking passports, which makes them a promising, adaptable tool for treating disease and creating valuable biotech products.
t cell engagersmedical
"developing innovative gamma-delta (γδ) T cell therapies and T cell engagers (TCEs) for cancer"
T cell engagers are engineered molecules that act like a matchmaker or bridge, linking a patient’s T cells (immune cells that kill infected or cancerous cells) directly to diseased cells so the immune system can destroy them. For investors, they matter because successful T cell engagers can become high-value therapies with steep clinical and regulatory milestones that drive a biotech company’s revenue potential and share price, while failures or safety issues can rapidly reduce valuation.
car-gamma-delta t cellsmedical
"emerging engineering strategies, including CAR-γδ T cells, cytokine-armored γδ T cells"
CAR-gamma-delta T cells are a type of immune cell (gamma-delta T cells) that have been genetically given a chimeric antigen receptor — think of giving patrol officers a customized GPS that directs them to specific disease cells to find and kill. For investors, they matter because they promise some potential advantages over conventional engineered T-cell therapies — including lower risk of certain immune complications, a better ability to penetrate diverse tumors, and the possibility of off-the-shelf manufacturing that could lower costs and broaden market reach.
checkpoint inhibitorsmedical
"combination approaches involving checkpoint inhibitors, chemotherapy, cytokines, and bispecific antibodies"
Checkpoint inhibitors are drugs that help the immune system recognize and attack cancer cells by blocking certain proteins that normally keep immune responses in check. They act like brakes being released on the immune system, allowing it to target tumors more effectively. These medicines are important for investors because they represent a promising area of cancer treatment with growing research, development, and commercial potential.
bispecific antibodiesmedical
"combination approaches involving checkpoint inhibitors, chemotherapy, cytokines, and bispecific antibodies"
Engineered proteins that can attach to two different biological targets at once, like a two-headed key that fits two locks simultaneously; in medicine they often link immune cells to diseased cells or block two disease pathways at the same time. Investors care because this dual-action design can improve effectiveness or open new treatment options, but it also raises development complexity, manufacturing cost and regulatory risk, affecting a biotech company’s value and partnerships.
graft-versus-host diseasemedical
"off-the-shelf γδ T cell therapies due to the cells’ lack of graft-versus-host disease (GvHD)-associated alloreactivity"
Graft-versus-host disease is a complication that can occur after a transplant using donor immune cells, where those transplanted cells attack the recipient’s organs and skin instead of protecting them; imagine a new security team mistaking the building’s occupants for intruders. It matters to investors because its likelihood, severity, and available treatments shape clinical trial results, drug approval chances, safety labels, patient outcomes, and the commercial potential of therapies aimed at preventing or managing the condition.
allogeneicmedical
"highlights the potential for allogeneic “off-the-shelf” γδ T cell therapies"
Allogeneic describes a process or material involving different individuals of the same species, such as cells, tissues, or organs donated from one person to another. It is important to investors because products or treatments based on allogeneic sources can enable scalable, off-the-shelf solutions, potentially reducing costs and increasing accessibility in healthcare and biotech industries.
major histocompatibility complexmedical
"recognize stress-associated signals independent of major histocompatibility complex (MHC) restriction"
A major histocompatibility complex (MHC) is a group of genes that make proteins acting like ID badges on cells, helping the immune system tell the body’s own cells from invaders. It matters to investors because MHC differences drive how people respond to vaccines, immunotherapies and transplant procedures, affecting clinical trial results, drug effectiveness, patient eligibility and ultimately the commercial success of biopharma products.
Review Highlights Emerging Engineering Strategies Including Combination Approaches Designed to Enhance Anti-Tumor Activity, Gamma-Delta T cell Engagers, CAR-Gamma-Delta T Cells and Cytokine-Armored Cells
NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- IN8bio, Inc. (NASDAQ: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta (γδ) T cell therapies and T cell engagers (TCEs) for cancer and autoimmune diseases, today announced the publication of a review article titled: “Harnessing γδ T cells through engineering and combination therapies” in the journal Nature Communications. IN8bio Chief Scientific Officer (CSO) Lawrence Lamb, Ph.D. was a contributing author to the review, which highlights advances in γδ T cell engineering, combination approaches, and clinical development strategies designed to improve anti-tumor efficacy across both solid tumors and hematologic cancers.
γδ T cells differ from conventional alpha-beta T cells through their ability to recognize stress-associated signals independent of major histocompatibility complex (MHC) restriction. This potentially solves problems associated with therapeutic development and enables them to target tumors that evade traditional immune responses. The publication reviews emerging engineering strategies, including CAR-γδ T cells, cytokine-armored γδ T cells, TCE approaches, and antibody-secreting γδ T cells, as well as combination approaches involving checkpoint inhibitors, chemotherapy, cytokines, and bispecific antibodies.
“We are pleased Nature Communications published this review highlighting the rapid progress and growing momentum across the γδ T cell field,” said Lawrence Lamb, CSO and scientific co-founder of IN8bio. “The publication highlights the unique biological properties of γδ T cells and their potential to address important limitations associated with current immunotherapy approaches, particularly in difficult-to-treat solid tumors. We believe advances in engineering, manufacturing, and combination strategies are continuing to expand the therapeutic potential of γδ T cells across oncology and autoimmune diseases.”
The publication also highlights the potential for allogeneic “off-the-shelf” γδ T cell therapies due to the cells’ lack of graft-versus-host disease (GvHD)-associated alloreactivity, as well as growing clinical evidence supporting γδ T cell therapies across hematologic malignancies and solid tumors, including glioblastoma.
In addition, the review discusses how γδ T cells may function as orchestrators of immune surveillance through their ability to recognize heterogeneous tumor-associated stress signals and potentially overcome mechanisms of immune escape commonly observed in advanced cancers.
This review was authored by an international group of five highly respected oncologists and immunologists including Lawrence Lamb, PhD and IN8bio’s Scientific Advisory Board (SAB) member Jonathan Fisher, BM, PhD, MRCPCH from University College London. There are an increasing number of actively recruiting γδ T cell clinical trials globally, reflecting growing academic and industry interest in the platform across cancer and autoimmune diseases.
IN8bio is a clinical-stage biopharmaceutical company developing γδ T cell and γδ T cell engager (TCE) product candidates to address unmet medical needs. γδ T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The Company’s pipeline is anchored by INB-600, a novel γδ T cell engager platform with potential applications across oncology and autoimmune indications. IN8bio is also advancing INB-100, an allogeneic γδ T cell candidate for adult patients with high-risk leukemias undergoing haploidentical stem cell transplantation, and INB-200/400, an autologous genetically modified γδ T cell candidate for newly diagnosed glioblastoma (GBM). For more information about IN8bio, visit www.IN8bio.com.
What did IN8bio (NASDAQ: INAB) announce on June 3, 2026 about Nature Communications?
IN8bio announced publication of a γδ T cell review article in Nature Communications. According to IN8bio, the paper covers engineering strategies, combination therapies and clinical development approaches aimed at improving anti-tumor efficacy in solid tumors and hematologic cancers.
What is the focus of IN8bio's Nature Communications review on gamma-delta T cells (INAB)?
The review focuses on engineering and combination therapies for γδ T cells. According to IN8bio, it discusses CAR-γδ T cells, cytokine-armored γδ T cells, T cell engagers, antibody-secreting γδ T cells and combinations with checkpoint inhibitors, chemotherapy, cytokines and bispecific antibodies.
How do gamma-delta T cells differ from conventional T cells in IN8bio's research (INAB)?
Gamma-delta T cells recognize stress-associated signals independently of MHC restriction. According to IN8bio, this feature may address challenges in therapeutic development and allow targeting of tumors that evade traditional immune responses seen with conventional alpha-beta T cells.
What potential do allogeneic off-the-shelf gamma-delta T therapies have in IN8bio’s platform?
Allogeneic γδ T therapies may be feasible due to limited GvHD-associated alloreactivity. According to IN8bio, this characteristic supports development of off-the-shelf γδ T products and aligns with growing clinical evidence across hematologic malignancies and solid tumors, including glioblastoma.
Who contributed to IN8bio's Nature Communications gamma-delta T cell review?
The review was written by an international group of five oncologists and immunologists. According to IN8bio, contributors include CSO Lawrence Lamb, PhD and Scientific Advisory Board member Jonathan Fisher, BM, PhD, MRCPCH from University College London, reflecting broad academic collaboration.
